Bifidobacterium longum CECT 7894 Improves the Efficacy of Infliximab for DSS-Induced Colitis via Regulating the Gut Microbiota and Bile Acid Metabolism

Background: Recent evidence suggests that the changes in gut microbiota and its metabolites could predict the clinical response of anti-tumor necrosis factor (TNF) agents, such as infliximab (IFX). However, whether manipulation of the gut microbiota can enhance the efficacy of anti-TNF agents remain...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Fangfei Xiao, Fang Dong, Xiaolu Li, Youran Li, Guangjun Yu, Zhanju Liu, Yizhong Wang, Ting Zhang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2022-08-01
Edice:	Frontiers in Pharmacology
Témata:	inflammatory bowel diseases Bifidobacterium longum infliximab gut microbiota bile acids
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2022.902337/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!